Idorsia

Idorsia is a Switzerland-based biopharmaceutical company founded in 2017, specializing in the discovery and development of innovative small molecule drugs. The firm focuses on transforming therapeutic options through a robust research pipeline and advanced clinical development. By leveraging a dedicated research center, Idorsia aims to address significant unmet medical needs across global markets, utilizing a scientific approach to drug discovery that prioritizes patient outcomes and long-term therapeutic efficacy.

Operating with 500-1,000 employees, the company maintains a highly specialized workforce focused on pharmaceutical innovation, clinical trial management, and commercialization. Meet Idorsia's team to understand the organizational structure and the leadership driving their drug discovery initiatives. The company’s operational footprint supports its mission to bring novel medicines to patients worldwide, maintaining a strategic presence in key international regions including Europe, Asia, and North America, ensuring a comprehensive approach to global healthcare delivery.

Idorsia is publicly traded on the SIX Swiss Exchange under the ticker IDIA. The company maintains a strong balance sheet, reporting annual revenue of $293.8M. Explore financial highlights to review detailed metrics, including recent stock issuance and debt financing activities that support their ongoing research and development efforts. With a commitment to scientific excellence, Idorsia continues to expand its portfolio of therapeutic candidates, positioning itself as a significant player in the global healthcare sector while navigating the complexities of the modern pharmaceutical landscape.